ribavirin has been researched along with Hepatic Insufficiency in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brainard, DM; Curtis, C; Lasseter, K; Lawitz, E; Ling, KHJ; Marbury, T; Mathias, A; Mogalian, E; Moorehead, L; Murray, B; Osinusi, A; Perry, R | 1 |
| Christian, A; Gallimore, AM; Godkin, A; Hills, RK; Jones, E; Pembroke, T; Wang, EC | 1 |
| Awni, WM; Bernstein, BM; Ding, B; Dutta, S; Khatri, A; Lawitz, EJ; Marbury, TC; Menon, RM; Mullally, VM; Podsadecki, TJ | 1 |
| Buclin, T; Chtioui, H | 1 |
| Khatri, A; Menon, R | 1 |
| Andriulli, A; Caruso, N; Iacobellis, A; Niro, GA; Perri, F; Valvano, MR | 1 |
| Cacoub, P; Geri, G; Imbert-Bismut, F; Poynard, T; Saadoun, D; Sène, D; Terrier, B | 1 |
2 trial(s) available for ribavirin and Hepatic Insufficiency
| Article | Year |
|---|---|
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; Female; Hepatic Insufficiency; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine; Young Adult | 2018 |
Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Function Tests; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2015 |
5 other study(ies) available for ribavirin and Hepatic Insufficiency
| Article | Year |
|---|---|
The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Biopsy; Case-Control Studies; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Flow Cytometry; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon-alpha; Killer Cells, Natural; Linear Models; Liver; Lymphocyte Activation; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 1; Ribavirin; Severity of Illness Index; Treatment Failure; Viral Load | 2014 |
Pharmacokinetics in hepatic impairment: Mind the protein binding.
Topics: Anilides; Carbamates; Female; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Uracil | 2015 |
Reply to "Pharmacokinetics in hepatic impairment: Mind the protein binding".
Topics: Anilides; Carbamates; Female; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Uracil | 2015 |
Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab.
Topics: Aged; Alanine Transaminase; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Biomarkers; Drug Monitoring; Female; Hepacivirus; Hepatic Insufficiency; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Rituximab; Treatment Outcome; Viral Load | 2012 |